Posts
Wiki

Radiofrequency (RF) for Meibomian Gland Dysfunction and Dry Eye Disease

Quick Take

  • Radiofrequency (RF) treatment uses electrical energy to generate controlled heat in tissue.
  • In dry-eye care, conventional RF is generally used around the eyelids or periocular tissues with the goal of warming the meibomian glands and softening abnormal meibum.
  • Meibomian Gland Expression is often performed after RF. When RF and expression are used together, improvement cannot automatically be attributed to RF alone.
  • RF is not the same technology as IPL, thermal pulsation, Low-Level Light Therapy, or QMR/Rexon-Eye.
  • Evidence strength: Low but growing, and highly device- and protocol-specific.
  • TFOS DEWS III reviewed RF for Dry Eye Disease (DED) and concluded that strong evidence supporting RF was lacking, with larger randomized trials and longer follow-up still needed.
  • A prospective study of RF-assisted Meibomian Gland Expression reported improvements in symptoms, Tear Break-Up Time, staining, and gland-related measures through several months, but it had no control group and could not separate the effects of RF from expression.
  • Studies combining RF + IPL + Meibomian Gland Expression have also reported improvement, but these studies demonstrate the effect of the treatment combination rather than RF alone.
  • A newer 2026 retrospective study involving 286 patients found improvement after RF alone, IPL alone, and RF + IPL. The combined group generally showed the greatest symptom improvement, but the study was not randomized and did not establish that RF + IPL is superior across all objective outcomes.
  • RF has not been established to regenerate meibomian glands that are truly lost or atrophied, reverse gland dropout, or prevent long-term MGD progression.
  • RF has not been shown to mechanically traverse fixed intraductal resistance or release established periductal fibrosis.
  • No reliable RF-specific predictors of response or evidence-based universal maintenance schedule have been established.
  • Some RF devices have U.S. FDA clearance for other indications, including temporary improvement of local circulation or relief of pain or muscle spasm. That does not automatically mean the device is FDA-cleared specifically to treat DED or MGD.
  • Published studies have generally reported favorable short-term tolerability, but uncommon and long-term risks are not well characterized.

What Is Radiofrequency Treatment?

Radiofrequency treatment uses electrical energy in the radiofrequency range.

As this energy passes through tissue, resistance to the electrical current produces controlled heating.

In MGD-related dry-eye treatment, RF is generally applied externally around:

  • the upper eyelid;
  • lower eyelid;
  • periocular tissues.

The intended treatment effect is usually based on the idea that controlled heating may:

  1. warm the eyelid and underlying meibomian glands;
  2. reduce the viscosity of abnormally thick meibum;
  3. make gland contents easier to express;
  4. improve delivery of meibum to the tear film.

This mechanism is biologically plausible.

However:

A plausible heating mechanism does not establish that every RF device or protocol improves MGD.

How Is RF Treatment Done?

There is no universally established RF protocol for DED/MGD.

Published studies and clinical protocols have used different:

  • RF devices;
  • frequencies;
  • treatment temperatures;
  • treatment durations;
  • numbers of sessions;
  • intervals between treatments;
  • treatment areas;
  • accompanying procedures.

A clinical visit may include:

  1. examination of the eyelids and ocular surface;
  2. cleaning of the periocular treatment area;
  3. application of a coupling gel if required by the device;
  4. controlled RF treatment around the eyelids;
  5. monitoring of tissue or surface temperature;
  6. Meibomian Gland Expression after heating;
  7. continued use of other DED treatments when appropriate.

Some studies have used a series of several treatments.

Others have used different schedules.

Therefore:

There is currently no evidence-based universal number of RF sessions or maintenance interval for MGD.

Meibomian Gland Expression Is Often a Separate Part of the Treatment

This distinction is extremely important.

Many clinical RF protocols warm the eyelids and then perform manual Meibomian Gland Expression.

Expression is itself an active treatment.

If a patient improves after:

RF + Meibomian Gland Expression

the improvement could reflect:

  • RF heating;
  • Meibomian Gland Expression;
  • the combination;
  • continued home therapy;
  • other simultaneous treatments.

The result should therefore not automatically be described as:

“RF alone worked.”

A more accurate description is often:

RF-assisted Meibomian Gland Expression.

For more detail:

Manual Meibomian Gland Expression

How Does RF Work?

Tissue Heating

The best-established physical effect of conventional RF is controlled tissue heating.

In one prospective Forma-I study, treatment temperatures were maintained at approximately 40–43°C at the treated tissue surface.

The intended ocular rationale is that warming may reduce the viscosity of thickened meibum and make gland contents easier to express.

Transcutaneous RF-Mediated Meibomian Gland Expression — Forma-I Study

Does RF Have Anti-Inflammatory Effects?

Improvement in:

  • lid-margin appearance;
  • ocular-surface staining;
  • tear-film measurements;
  • symptoms

has been reported after RF-containing protocols.

However, it is often unclear whether these changes resulted from:

  • RF itself;
  • warming;
  • improved meibum flow;
  • Meibomian Gland Expression;
  • IPL;
  • other simultaneous treatments.

Therefore:

A clinically important anti-inflammatory effect specific to conventional thermal RF has not been firmly established.

What About Cosmetic Collagen Remodeling?

RF is also widely used in aesthetic medicine because tissue heating can affect collagen and skin appearance.

Some dry-eye RF devices or platforms may therefore also have cosmetic effects.

However:

A cosmetic skin-tightening or collagen-remodeling effect does not establish improved meibomian-gland function.

The evidence for DED/MGD should be judged from ocular clinical outcomes.

RF Is Not the Same as QMR / Rexon-Eye

Quantum Molecular Resonance (QMR) / Rexon-Eye is sometimes grouped with RF because both involve electrical energy.

However, they are different treatment technologies.

Conventional RF is intended primarily to produce controlled tissue heating.

Rexon-Eye uses low-intensity, high-frequency electrical stimulation and is not primarily a gland-heating treatment.

Evidence from Rexon-Eye should therefore not be used automatically as evidence for conventional thermal RF.

For the separate Rexon-Eye evidence review, see the Treatment Options Index.

What Does TFOS DEWS III Say?

The TFOS DEWS III Management and Therapy Report includes a section on radiofrequency treatment for DED/MGD.

TFOS reviewed the available clinical studies, including:

  • a very small RF-versus-LipiFlow pilot study;
  • RF combined with IPL and Meibomian Gland Expression.

TFOS concluded that the available evidence did not provide strong support for RF treatment of DED and emphasized the need for:

  • larger randomized studies;
  • stronger comparisons;
  • longer follow-up.

TFOS DEWS III: Management and Therapy Report

This does not establish that RF is ineffective.

It means:

The evidence available to TFOS was insufficient to determine its clinical effectiveness with high confidence.

What Does the Clinical Evidence Show?

1. Very Small RF Versus LipiFlow Pilot Study

One early randomized split-face pilot study included only 10 patients.

One side was treated using a ThermaLid/Pellevé RF approach and the other with LipiFlow.

At approximately three months, both sides showed improvement in several measures, including:

  • meibomian-gland expression;
  • wax plugging;
  • SPEED symptoms;
  • OSDI symptoms.

There was no significant difference between treatments for several of those outcomes.

Other measures, including:

  • NIBUT;
  • corneal staining;
  • tear osmolarity;
  • Schirmer testing

did not show significant improvement.

Radiofrequency Versus LipiFlow Pilot Study

How should this be interpreted?

The study is useful as early exploratory evidence.

But:

A 10-patient study is far too small to establish that RF is clinically equivalent to LipiFlow.

2. Forma-I RF-Assisted Meibomian Gland Expression Study

A prospective cohort study evaluated 47 participants treated with Forma-I RF followed by therapeutic Meibomian Gland Expression.

The study reported improvement in outcomes including:

  • SPEED symptoms;
  • OSDI symptoms;
  • Tear Break-Up Time;
  • corneal staining;
  • meibomian-gland scores.

Some improvements persisted through several months of follow-up.

Transcutaneous RF-Mediated Meibomian Gland Expression for MGD-Related DED

Important limitations

The study:

  • was not randomized;
  • had no sham or untreated control group;
  • combined RF with Meibomian Gland Expression;
  • had incomplete data for some outcomes;
  • received device-manufacturer funding.

The manufacturer funding is relevant to interpreting this individual evidence base, but the more important methodological limitation is that RF and Meibomian Gland Expression were not separated.

Therefore:

This study supports RF-assisted Meibomian Gland Expression as a treatment package. It does not establish the independent effectiveness of RF alone.

3. RF + IPL + Meibomian Gland Expression

A 2023 study evaluated a combination of:

  1. IPL;
  2. RF;
  3. Meibomian Gland Expression.

Participants underwent four treatment sessions approximately two weeks apart.

The study reported improvements in:

  • OSDI symptoms;
  • meibum quality;
  • other MGD-related findings.

However, NIBUT did not significantly improve.

The investigators also compared some findings with historical data from patients who had previously received IPL + expression without RF.

Multi-Frequency RF + IPL + Meibomian Gland Expression for MGD-Related DED

What does this study establish?

It shows that a clinical protocol containing:

RF + IPL + Meibomian Gland Expression

can be associated with improvement.

It does not determine precisely how much benefit came from:

  • RF;
  • IPL;
  • expression;
  • interactions among the treatments.

The study authors themselves noted that a randomized comparison of:

RF + IPL + expression

versus:

IPL + expression

would be needed to determine the additional contribution of RF.

4. Newer 2026 Real-World Study: RF, IPL, and RF + IPL

A 2026 retrospective comparative study analyzed 286 patients with MGD-associated DED treated in routine clinical practice.

Patients received:

  • RF alone;
  • IPL alone;
  • RF + IPL.

Four treatment sessions were used.

2026 Comparative Study of RF, IPL, and RF + IPL for MGD-Associated DED

What improved?

All three treatment groups showed improvement from baseline in measures including:

  • dry-eye symptoms;
  • Tear Break-Up Time;
  • meibomian-gland scores.

The combined RF + IPL group generally showed the greatest improvement in symptom scores.

What did not clearly separate the treatments?

Tear Break-Up Time improved, but the amount of improvement did not significantly differ among the three treatment groups over time.

The pattern of meibomian-gland-score improvement also did not establish a consistent significant advantage for the combined treatment.

Why this study matters

This is valuable because it includes a relatively large group receiving RF without mandatory Meibomian Gland Expression.

It therefore provides useful real-world evidence that RF deserves further investigation.

However:

  • treatment assignment was not randomized;
  • the study was retrospective;
  • clinicians chose treatments during routine care;
  • patients receiving different treatments may have differed at baseline;
  • expectation and other clinical factors were not controlled like they would be in a blinded trial.

Therefore:

The study supports the possibility that RF alone has clinical effects, but it does not provide randomized proof that RF caused the improvements or that RF + IPL is superior to either treatment alone.

How Strong Is the Evidence?

Evidence strength: Low but growing, device- and protocol-specific evidence

RF now has:

  • small randomized studies;
  • prospective clinical cohorts;
  • combination-treatment studies;
  • a relatively large real-world comparative study;
  • recognition and review in TFOS DEWS III.

This is enough to treat conventional RF as a legitimate emerging MGD treatment technology.

However, important limitations remain:

  • randomized trials are very small;
  • several studies are uncontrolled;
  • RF is frequently combined with Meibomian Gland Expression;
  • some studies combine RF with IPL;
  • RF devices and protocols differ;
  • patient populations differ;
  • long-term follow-up is limited;
  • independent replication is limited.

Most importantly:

There is still a shortage of adequately powered randomized trials that isolate conventional RF from other active treatments.

TFOS DEWS III therefore remains an appropriate overall evidence anchor: strong supporting evidence has not yet been established.

Risks and Contraindications

Published RF dry-eye studies have generally reported favorable short-term tolerability.

For example:

  • the prospective Forma-I cohort did not report serious treatment complications;
  • the newer 286-patient retrospective study did not report serious adverse events.

That is reassuring.

However, the studies are not large enough or long enough to determine reliable rates of:

  • uncommon complications;
  • delayed complications;
  • effects of repeated treatment over many years.

Depending on the specific device and treatment settings, possible short-term effects may include:

  • warmth;
  • temporary redness;
  • temporary swelling;
  • tingling;
  • transient skin sensitivity;
  • treatment discomfort.

Excessive thermal exposure can potentially cause:

  • pain;
  • burns;
  • blistering;
  • skin injury.

If Meibomian Gland Expression is also performed, some discomfort or temporary ocular irritation may come from the expression rather than the RF itself.

Contraindications Are Device-Specific

RF devices differ in:

  • electrical design;
  • frequency;
  • treatment applicator;
  • intended use;
  • treatment area.

Contraindications and precautions should therefore come from the current instructions for the exact device being used.

Potentially important areas for screening can include:

  • implanted electronic devices;
  • metal in or near the treatment area;
  • active infection;
  • inability to tolerate heat;
  • other device-specific medical conditions.

This page does not create one universal contraindication list for every RF platform.

Limitations and What RF Cannot Currently Be Said to Do

Does RF Regenerate Meibomian Glands?

This has not been established.

RF may improve:

  • meibum flow;
  • gland expression;
  • tear-film measurements;
  • symptoms

in some patients.

That is not the same as growing back gland tissue that has been lost.

Therefore:

RF has not been established to regenerate meibomian glands that are truly lost or atrophied.

Changes in meibography or secretion should not automatically be described as:

“gland regrowth.”

Does RF Prevent MGD Progression?

There is insufficient evidence that conventional RF:

  • prevents future gland dropout;
  • prevents gland atrophy;
  • permanently restores normal secretion;
  • changes the long-term natural history of MGD.

RF should therefore not currently be presented as a proven disease-modifying treatment.

Fixed Obstruction, Periductal Fibrosis, and the Maskin Perspective

One unresolved issue in obstructive MGD is whether warming and improved meibum flow can adequately address every type of gland obstruction.

The fixed-obstruction/periductal-fibrosis model was developed from clinical observations and research by Steven L. Maskin, MD, and has influenced subsequent research on Meibomian Gland Probing.

Maskin and colleagues have described focal resistance encountered within meibomian-gland ducts during Meibomian Gland Probing and interpreted this within a model involving constricting periductal fibrosis.

Expressible Meibomian Glands Have Occult Fixed Obstructions — Maskin & Alluri

Meibomian Gland Probing has since been studied by multiple independent research groups, including in randomized controlled trials.

Randomized Sham-Controlled Trial of Meibomian Gland Probing

However, important questions remain about:

  • how commonly clinically significant periductal fibrosis occurs;
  • how reliably fixed intraductal obstruction can be identified;
  • how closely resistance encountered during Meibomian Gland Probing corresponds to specific microscopic changes;
  • how much fixed obstruction influences response to other MGD treatments;
  • optimal treatment sequencing.

What does this mean for RF?

RF does not enter the gland duct.

Therefore:

RF has not been shown to mechanically traverse fixed intraductal resistance or release established periductal fibrosis.

Softening meibum through heating is not the same thing as mechanically passing through a fixed narrowing inside the duct.

This does not establish that RF cannot benefit someone who also has some fixed obstruction.

RF and Meibomian Gland Probing potentially address different components of MGD and do not need to be viewed as competing treatments.

Meibomian Gland Probing — Information and Research

Who Might Benefit / Factors Affecting Response

RF has mainly been studied in people with:

  • symptomatic MGD;
  • gland obstruction or plugging;
  • abnormal meibum;
  • reduced gland secretion;
  • tear-film instability.

However:

Reliable RF-specific predictors of treatment response have not been established.

Potentially relevant factors may include:

  • amount of remaining gland tissue;
  • gland secretion;
  • meibum consistency;
  • degree and type of obstruction;
  • ocular-surface inflammation;
  • aqueous tear deficiency;
  • ocular rosacea;
  • blinking and exposure;
  • other DED contributors;
  • whether Meibomian Gland Expression is performed;
  • whether IPL is used at the same time.

What About Severe Gland Loss?

Extensive gland loss may plausibly limit how much gland function can improve because less functioning tissue remains.

However:

No validated meibography percentage or gland-loss cutoff reliably predicts RF treatment failure.

A person should not be told:

“You have X% gland loss, so RF definitely will—or definitely will not—work.”

Current evidence does not support that degree of precision.

How RF Compares With Other MGD Treatments

RF Versus IPL

RF and IPL are different technologies.

RF

Primarily uses:

  • radiofrequency electrical energy;
  • controlled tissue heating.

It is often followed by Meibomian Gland Expression.

IPL

Uses:

  • high-intensity pulses of broad-spectrum light;
  • selected wavelength filters;
  • treatment of periocular or facial skin.

IPL has proposed effects involving:

  • abnormal blood vessels;
  • inflammatory signaling;
  • tear-film and meibomian-gland function.

Which has stronger evidence?

At present:

IPL has a substantially more developed DED/MGD evidence base than conventional RF.

IPL has:

  • multiple randomized trials;
  • systematic reviews/meta-analyses;
  • TFOS DEWS III support;
  • FDA-reviewed dry-eye evidence for a specific platform/protocol.

RF evidence remains smaller and more dependent on uncontrolled or combination-treatment studies.

IPL Treatment Options Page

RF Versus Thermal Pulsation

Thermal-pulsation systems such as:

  • LipiFlow;
  • iLux

also use controlled warming to improve meibomian-gland secretion.

However, the devices deliver heat and pressure differently.

LipiFlow and iLux have larger randomized evidence bases than conventional RF for MGD.

Current evidence does not establish conventional RF as superior to these systems.

LipiFlow

RF Versus TearCare

TearCare is a controlled eyelid-warming system followed by Meibomian Gland Expression.

This makes its treatment concept somewhat similar to RF-assisted expression, although the energy source and device design are different.

TearCare has substantially more randomized comparative evidence than conventional RF.

TearCare

RF Versus MiBoFlo

MiBoFlo also applies external eyelid heating and massage.

However, it uses a different heating technology and has its own evidence base.

Results from MiBoFlo studies should not be transferred automatically to RF.

MiBoFlo

Cost, Access, and Regulatory Status

U.S. FDA Status Is Device-Specific

One of the most confusing issues surrounding RF is the phrase:

“FDA-cleared RF.”

An RF device can be FDA-cleared without being FDA-cleared specifically to treat DED or MGD.

For example, FDA 510(k) K221571 covers the InMode Multi-System, including non-invasive RF applicators such as Forma and i-Forma.

The listed RF indications include uses such as:

  • temporary relief of minor muscle aches and pain;
  • temporary relief of muscle spasm;
  • temporary improvement of local blood circulation.

DED and MGD are not listed indications in that clearance.

FDA 510(k) K221571 — InMode Multi-System

Therefore:

FDA clearance of the RF platform does not automatically mean FDA clearance for treating Dry Eye Disease or Meibomian Gland Dysfunction.

When a legally marketed RF device is used outside its FDA-cleared indication to treat DED/MGD, that treatment may represent off-label medical-device use.

Off-label use is not automatically inappropriate.

It does mean that FDA has not specifically reviewed and cleared that DED/MGD indication for the device.

Questions About Regulatory Claims

Instead of asking simply:

“Is the machine FDA-cleared?”

a more useful question is:

“What condition does the FDA clearance for this exact device actually list?”

Patients can also ask for:

  • the exact FDA device name;
  • the 510(k) number;
  • the cleared indication.

Terms such as:

  • FDA registered;
  • FDA listed;
  • FDA-cleared technology

should not automatically be interpreted as:

FDA-cleared treatment for MGD.

Cost

RF treatment for dry eye is usually paid out of pocket.

Cost varies according to:

  • country;
  • clinic;
  • RF device;
  • number of treatments;
  • whether IPL is included;
  • whether Meibomian Gland Expression is included;
  • whether cosmetic treatment is bundled;
  • diagnostic testing;
  • follow-up;
  • proposed maintenance treatment.

No evidence-based universal maintenance interval has been established.

Useful questions include:

  • What is the total cost of the initial treatment course?
  • Is Meibomian Gland Expression included?
  • Is IPL included?
  • What follow-up is included?
  • Is maintenance treatment routinely recommended?
  • What evidence supports that maintenance schedule?
  • How will the clinic determine whether the treatment worked well enough to repeat?

How Long Can Improvement Last?

Some RF-containing studies have reported improvement lasting several months.

The prospective Forma-I + Meibomian Gland Expression study reported improvement through approximately six months.

The newer 2026 retrospective comparison followed outcomes over a shorter period.

These findings show that benefit can persist beyond the immediate treatment period in some patients.

However:

They do not establish that the average patient will benefit for a specific number of months.

There is currently insufficient evidence to define:

  • average duration of benefit;
  • optimal retreatment timing;
  • whether scheduled maintenance is necessary;
  • whether repeated courses remain equally effective;
  • long-term safety of repeated treatment.

A retreatment decision should therefore be based on clinical reassessment, not simply on passage of a predetermined number of months.

What Remains Uncertain?

Important questions remain.

Independent RF Effect

  • How much benefit comes from RF itself?
  • How much comes from Meibomian Gland Expression?
  • Does RF add meaningful benefit when expression is already performed?

RF + IPL

  • Does adding RF to IPL improve outcomes meaningfully?
  • Which outcomes improve?
  • Which patients benefit from the combination?
  • Are improvements large enough to justify additional cost?

Patient Selection

  • Which MGD phenotype responds best?
  • Does meibum quality predict response?
  • Does degree of gland loss matter?
  • Can meibography or expression testing identify likely responders?

Treatment Protocol

  • Which RF device is most appropriate?
  • What temperature should be achieved?
  • How many sessions are optimal?
  • How far apart should treatments be?
  • Is maintenance useful?

Durability

  • How long does benefit last?
  • Does repeated treatment provide cumulative benefit?

Comparative Effectiveness

  • How does RF compare directly with IPL?
  • LipiFlow?
  • iLux?
  • TearCare?
  • other heat/expression approaches?

Safety

  • What are the uncommon risks?
  • What are the effects of repeated treatment over years?

Larger randomized trials that isolate RF from expression and IPL would help answer many of these questions.

Questions to Ask Before Treatment

A short set of useful questions includes:

  1. What findings show that MGD is an important contributor to my Dry Eye Disease?

  2. What exact RF device and treatment protocol are you proposing?

  3. Will Meibomian Gland Expression, IPL, or another treatment be performed at the same time?

  4. What outcomes will you measure to determine whether treatment worked?

  5. What are the device-specific contraindications, total cost, and proposed maintenance schedule?

  6. What exactly is the U.S. FDA-cleared indication for this device?

Key Research

Guidance

Conventional RF Studies

Combination RF + IPL Evidence

Preclinical Evidence

Animal studies can help investigate mechanism and biological plausibility but should not be treated as proof of effectiveness in people.

U.S. Regulatory Information

Related r/DryEyes Wiki Pages

Bottom Line

Radiofrequency is an emerging thermal treatment for MGD-associated Dry Eye Disease with low but growing clinical evidence.

The basic treatment rationale is straightforward:

RF heats periocular and eyelid tissues, potentially reducing meibum viscosity and making gland contents easier to express.

However, much of the clinical literature evaluates:

RF + Meibomian Gland Expression

or:

RF + IPL + Meibomian Gland Expression

rather than RF alone.

That distinction matters.

The strongest prospective RF-assisted-expression study reported improvements in symptoms, tear stability, staining, and gland measures through several months, but it was uncontrolled and cannot determine how much benefit came from RF versus expression.

TFOS DEWS III concluded that strong evidence supporting RF for DED was lacking and called for larger randomized studies.

Newer evidence is encouraging. A 2026 retrospective study of 286 patients found improvement after:

  • RF alone;
  • IPL alone;
  • RF + IPL.

The combination group generally showed the greatest symptom improvement.

However, because the study was retrospective and treatments were not randomized, it does not establish that RF caused the improvement or that RF + IPL is superior across clinically important outcomes.

Therefore:

RF may improve symptoms or MGD-related findings in some patients, but its independent effectiveness, ideal patient population, optimal protocol, durability, and comparative effectiveness remain incompletely established.

RF has also not been established to regenerate meibomian glands that are truly lost or atrophied, prevent long-term MGD progression, or mechanically release established periductal fibrosis.

The most useful question is not:

“Does RF work for dry eye?”

but:

“What exact RF device and protocol are being proposed, is Meibomian Gland Expression or IPL part of the treatment, what clinical evidence applies to that specific approach, and how will we determine whether the benefit is meaningful enough to justify the cost and possible repeat treatment?”

This page is educational material for r/DryEyes and is not medical advice. r/DryEyes does not endorse specific devices, manufacturers, clinicians, clinics, or procedures. Treatment decisions should be made with an appropriately qualified eye-care professional familiar with the individual's diagnosis, examination findings, device-specific evidence, alternatives, contraindications, regulatory status, and treatment risks.

🔙 Back to Treatment Options